Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy

Two patients have died after receiving Celyad Oncology’s off-the-shelf CAR-T cell therapy CYAD-101. The colorectal cancer patients had similar pulmonary findings, prompting Celyad to voluntarily pause the trial while it investigates the events.